Abstract
This editorial examines incremental cost-effectiveness analysis as a decision-making tool to guide the allocation of scarce financial resources. BASKET (Basel Stent Kosten Effektivitats Trial) evaluated the cost-effectiveness of drug-eluting stents in a real-world setting. Results of this study are examined in relation to similar assessments and alternative plausible assumptions are explored and presented in the context of real-world sensitivity analysis.